AIM ImmunoTech Inc. AIM

AIM Company Overview

AIM ImmunoTech Inc. is a clinical-stage biotechnology company focused on the research and development of immunotherapy products intended to treat cancers, viral diseases, and immune system disorders. The company operates primarily within the biotechnology and biopharmaceutical industries, with a strategic emphasis on RNA-based therapeutics and immune modulation technologies. Its principal product candidate is Ampligen (rintatolimod), an experimental double-stranded RNA drug designed to activate toll-like receptor 3 (TLR3) pathways and stimulate innate immune responses. The company has also developed and maintained intellectual property associated with interferon-based technologies and antiviral therapeutic research.

The company traces its origins to Hemispherx Biopharma, Inc., which later rebranded as AIM ImmunoTech Inc. as part of a broader strategic repositioning around immunotherapy and oncology-focused development. According to public filings and corporate disclosures, AIM’s primary revenue historically has come from limited product sales, licensing activity, and financing transactions while it advances clinical development programs. The company’s strategic positioning is based on its proprietary nucleic acid technologies, long-standing clinical research history involving Ampligen, and its focus on diseases with limited approved treatment options, including certain cancers and chronic viral conditions.